image source

Eleven stocks in the munKNEE Pure-Play Psychedelic Stock Index went up 11.3% last week. Our index includes stocks trade between US $0.10 and US$1, and have market caps between $10 and $75 million. That being said, there are another 20 psychedelic stocks are not eligible for inclusion in the Index (i.e. even smaller). This article identifies, describes and tracks the performance of those "shroom" stocks divided into 4 segments for the sake of comparison. TM Editors Note: Keep in mind that using percentages for comparison is virtually meaningless when prices are this low.

Segment One

The following 10 psychedelic stocks are not included in the munKNEE Pure-Play Psychedelic Stock Index because their market caps are less than US$10M and/or they also trade for less than US$0.10/share. They are noteworthy nevertheless.

1. New Wave Holdings Inc. (TRMNF) +150.0% to US$0.05/share
   • New Wave will focus on supporting research on active psychedelic compounds, creation of consumer products based on functional mushrooms, and developing an IP portfolio focusing on psilocybin, LSD, MDMA, and ketamine derived treatments for neuropsychiatric diseases.
   • For more information on the company visit its website here.
2. Codebase Ventures Inc. (BKLLF) +71.4% to US$0.12/share
   • Codebase Ventures, an investment firm offering investors a diverse portfolio of opportunities, has a direct stake in Red Light Holland (see below), a publicly-traded entity involved in the psychedelic market through its subsidiary Titan Shrooms & Psychedelics.
   • For more information on the company visit its website here.
3. Red Light Holland Corp. (TRUFF) +66.7% to US$0.10/share
   • Produces and distributes legally sanctioned recreational psilocybin truffles in the Netherlands and has financial backing from investment firm Codebase Ventures (see above).
   • For more information on the company visit its website here.
4. Graph Blockchain Inc. (REGRF) + 50.0% to US$0.02/share
   • Acquired Shroom Street in a deal worth C$1 million and plans to pair its technology with an upcoming e-commerce platform for its psychedelic business purchase, set to launch at the end of 2020 for online sales in legal jurisdictions.
   • For more information on the company visit its website here.
5. Cybin Inc. (CLXPF) +25.7% to $0.93
   • Cybin Corp. is focused on psychedelic drug development, unique delivery mechanisms, improved novel compounds, and protocols that target psychiatric and neurological conditions.
   • For more information on the company visit its website here.
6. Lobe Sciences Ltd. (LOBE) +25.0% to US$0.05/share
   • Acquired Eleusian Biosciences Corp. in July to enable it to focus on developing proprietary technologies involving psilocybin, NAC, and MDMA for mTBI, PTSD, and brain injuries
     • For more information on the company visit its website here.
7. Better Plant Inc. (VEGGF) +/-0 %
   • Better Plant, formerly Yield Growth, develops, manufactures, markets, sells, and distributes plant-based products.
   • Its subsidiary, NeonMind Biosciences Inc., is launching a line of coffees infused with health optimizing medicinal functional (edible) mushrooms including reishi, cordyceps, lion's mane, and turkey tail mushrooms.
   • NeonMind is also engaged in research into developing a psilocybin (psychedelic) mushroom-based product for weight loss and has applied for a Section 56 Exemption to begin preclinical trials to study its pending psychedelic medicine patents.
   • intends to undertake clinical trials on the therapeutic effects of psilocybin and eventually launch branded products to support immune, cognitive, memory, and other brain functions.
   •  For more information on the company visit its website here.
8. EHave Inc. (EHVVF) +/-0%
   • Its focus is on delivering evidence-based interventions to patients to prevent or treat brain disorders or diseases through the use of digital therapeutics, psychedelics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes.
   • For more information on the company visit its website here.
9. Minerco Corp. (MINE) +/-0%
   • Acquired by psilocybin research and investment firm Mushrooms International Enterprises and is focused on finding the most effective strategies in producing and extracting the psilocybin from within psilocybin mushrooms.
   • Relocated its corporate offices to Jamaica as the country does not have any laws labeling magic mushrooms as illicit drugs and is in close proximity to the world's first magic mushroom research center, located at the University of the West Indies in Mona, Jamaica.
   • For more information on the company visit its website here.
10. Thoughtful Brands Inc. (PEMTF) +/-0%
    • Developed an e-commerce platform for hemp-derived cannabidiol (CBD) products in the U.S. and Europe and now plans to expand its operations in Europe to explore the potential of psychedelic treatments.
    • Brought in privately held Verrian, which owns a manufacturing facility in Germany, with the intention of making it the psychedelic research hub for psilocybin mushroom therapies against opioid addiction.
    • For more information on the company visit its website here.

On average the above 10 stocks went UP 25.6% last week.

Segment Two

Six other psychedelic stocks trade exclusively on the Canadian Securities Exchange (CSE) and in Canadian dollars (go here to convert into USD) and are worth keeping an eye on going forward, namely:

1. PharmaTher Inc. (PHRM) +92.9% to $0.27
   • PharmaTher, a wholly-owned subsidiary of Newscope Capital Corporation, is focused on the research and development of psychedelic pharmaceuticals, such as ketamine and psilocybin, to treat disorders such as Parkinson’s disease, depression, traumatic brain injury, and stroke, using panaceAI, its drug repurposing artificial intelligence platform.
     • PanaceAI leverages machine learning to curate and rank the most relevant drug interactions, binding affinities, drug-disease similarities, and structural comparison tools to make data-driven drug predictions and will serve as the Company’s product pipeline engine.
     • Upon further validation, panaceAI will be commercialized to acquire partnership opportunities with biotechnology and pharmaceutical companies globally.
     • For more information on the company visit its website here.
2. Psyched Wellness Ltd. (PSYC) +52.9% to $0.26
   • Psyched Wellness is dedicated to the production and distribution of psychedelic mushrooms and associated consumer packaged goods led by its flagship mushroom extract product, Amanita Muscaria infused tinctures which, when micro-dosed, has anecdotally been shown to soothe the body, ease physical distress and help with sleeping.
   • For more information on the company visit its website here.
3. Entheon Biomedical Corp. (ENTBF) +42.0% to $0.71
   • Entheon is focused on developing and commercializing a portfolio of safe and effective Dimethyltryptamine-based (DMT) psychedelic therapeutic products for the purposes of treating addiction and substance use disorders and to generate revenue through the sale of its DMT Products to physicians, clinics, and licensed psychiatrists in the United States, certain countries in the European Union and throughout Canada.
   • For more information on the company visit its website here.
4. Aion Therapeutic Inc. (AION) +/-0%
   • Its mission is to create an array of novel patent-protected therapeutic formulations using unique combinations of medical cannabis (THC & CBD) with psychedelic mushrooms (psilocybin), fungi (edible mushrooms), and other psychedelic and natural therapies to benefit patients with illnesses such as cancer, psychiatric disorders, addiction (opioid and alcohol), viral infections, obesity, chronic inflammation, and other such medical issues.
   • Acquired PCAI Pharma and its wholly-owned subsidiary AI Pharmaceuticals Jamaica Limited, a private corporation incorporated and operating under the laws of Jamaica, which provides Aion with:
     • a unique opportunity in that it is one of the very few countries in the world where mushrooms (both edible and psychedelic) have never been made illegal.
     • a major research and development opportunity through its partnership with Apollon Formularies Jamaica, Ltd. which allows Aion to focus on the development of combinatorial pharmaceuticals, nutraceuticals, and cosmeceuticals in a legal environment for this type of discovery.
   • The company believes it is in the unique position of being able to build a large portfolio of blocking patents while most of the rest of the world faces legal hurdles that limit efforts in this type of research and discovery and to that end has
     • Filed five patent applications with the United States Patent and Trademark Office pertaining to new treatments combining healing compounds in medical cannabis with healing compounds from mushrooms.
   • For more information on the company visit its website here.
5. Core One Labs Inc. (COOL) +/-0%
   • Sold its non-core assets in mid-October to allow it to focus on developing its thin strip technologies for use with psilocybin, as well as expanding the newly acquired psychedelic assets.
   • Has entered into a Letter of Intent to acquire all of the outstanding share capital of Vocan Biotechnologies Inc.
     • Vocan is a genetic engineering and biosynthesis research firm developing a proprietary fermentation system for the production of psilocybin API for the treatment of mental health illnesses, including addictions.
   • For more information on the company visit its website here.
6. Pure Extracts Technology Corp. (PULL) +3.3% to $0.63
   • The Company is currently focused on the cannabis and hemp sectors and is presently expanding its business to include functional (non-psychedelic) mushrooms extraction processes compatible with its existing infrastructure by the end of 2020.
     • To that end, the company has received a Dealers License from Health Canada which will enable them to buy, sell, test, and produce psychedelics in an EU GMP environment.
     • For more information on the company visit its website here.

On average the above 6 stocks went UP 50.0% last week.

Segment Three

The following company is doing research into the use of mescaline, a psychoactive compound similar to psilocybin that can be extracted from the Peyote cactus.

1. Nutritional High International Inc. (SPLIF) +/-0%
   • In June, while the company is primarily focused on developing and manufacturing branded cannabis products for the U.S. market, it purchased Kruzo LLC.
     • Kruzo is focused on developing products and conducting research on mescaline, a psychoactive compound similar to psilocybin that can be extracted from the Peyote cactus and will provide an important source of future product innovation and diversification.
     • Kruzo has a working relationship with Rangsit University in Thailand to investigate the utility and efficacy of combining mescaline and other Peyote alkaloids with traditional Asian herbal products as well as CBD and other cannabinoids.
   • In August the company acquired Psychedelic Science Corp. (PSC), a company focused on developing psychedelic cacti-based wellness and pharmaceutical products to address weight loss, insomnia, anxiety, and pain.
     • The PSC team is also assessing various non-psychoactive, cactus-based wellness products that are legal for sale and distribution in the U.S. and Canada.
   • For more information on the company visit its website here.

Segment Four

Below are the remaining three psychedelic drug stocks that make up the sector (they either trade in excess of $1/share and/or have a market cap in excess of $75M) with a description of their business and their performances last week:

1. Compass (CMPS) +40.3% (Mkt. Cap: $1.3B)
   • COMPASS has a psilocybin-based therapy for treatment-resistant depression in Phase 2 of clinical trials. For more information on the company visit its website here.
2. MindMed (MMEDF) +36.8%  (Mkt. Cap: $273.5M)
   • MindMed has three drug initiatives that use psychedelic mushrooms already in Phase 2 with several other initiatives in Phase 1 trials. For more information on the company visit its website here.
3. Field Trip (FTRPF) +3.0% (Mkt. Cap: $84.1M)
   • Field Trip is conducting advanced research on plant-based psychedelics such as ketamine as a treatment option for PTSD. For more information on the company visit its website here.

On average the above 3 stocks went UP 36.7% last week.